Relief Therapeutics: A Year of Progress and Promise

Relief Therapeutics, a biopharmaceutical company dedicated to delivering innovative treatment options for rare and debilitating diseases, has reported its 2024 financial results and provided a corporate update. The company's annual report, published on April 10, 2025, highlights a year of operational achievements, pipeline momentum, and a strengthened financial position. Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the company's commitment to delivering meaningful solutions for patients with unmet medical needs.

The company's financial health is robust, with around CHF 15 million in cash reserves and a CHF 50 million undrawn equity facility from its largest shareholder, GEM. This financial strength supports the company's ability to execute its development strategy and explore opportunities to maximize shareholder value. The company's core expertise in drug delivery systems and drug repurposing is expected to facilitate the successful launch of its innovative treatments.

Relief Therapeutics' clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic, and respiratory conditions. The company is particularly excited by the continued progress of RLF-OD032, a next-generation liquid sapropterin formulation for phenylketonuria (PKU), and RLF-TD011, a proprietary hypochlorous acid solution for epidermolysis bullosa (EB). These developments are expected to enhance the company's market position and diversify its revenue streams in the coming years.

The continued progress of RLF-OD032 and RLF-TD011 has significant strategic implications for Relief Therapeutics. These developments are expected to enhance the company's market position and diversify its revenue streams in the coming years. The company is looking forward to important clinical and regulatory milestones in 2025 for RLF-OD032 and RLF-TD011. Achieving these milestones could accelerate the path to market for these treatments, further enhancing the company's market position and revenue potential.

The company's 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company’s website. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.